



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Melissa Morales
✉ mmorales@binghamton.edu

RECEIVED 13 March 2025
ACCEPTED 14 March 2025
PUBLISHED 21 March 2025

CITATION

Spathis R, Kuriplach DR, Narvesen S, Eybs M, Huang K, Torres S, King M, Bagley E, Elustondo P, Lawlor MW, Nagaraju K and Morales M (2025) Corrigendum: Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis. *Front. Immunol.* 16:1593193. doi: 10.3389/fimmu.2025.1593193

COPYRIGHT

© 2025 Spathis, Kuriplach, Narvesen, Eybs, Huang, Torres, King, Bagley, Elustondo, Lawlor, Nagaraju and Morales. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis

Rita Spathis¹, Deeva Robles Kuriplach¹, Sabrina Narvesen¹, Matthew Eybs¹, Karen Huang¹, Steven Torres¹, Madison King¹, Elizabeth Bagley¹, Pia Elustondo², Michael W. Lawlor³, Kanneboyina Nagaraju¹ and Melissa Morales^{1*}

¹Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, United States, ²AGADA Biosciences, Halifax, NS, Canada, ³Department of Pathology & Laboratory Medicine, Medical College of Wisconsin and Diverge Translational Science Laboratory, Milwaukee, WI, United States

KEYWORDS

AAV9, *mdx*, Duchenne muscular dystrophy, DMD, gene therapy, immune response, TLR, complement

A Corrigendum on

Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis

by Spathis R, Kuriplach DR, Narvesen S, Eybs M, Huang K, Torres S, King M, Bagley E, Elustondo P, Lawlor MW, Nagaraju K and Morales M (2025) *Front. Immunol.* 16:1527840. doi: 10.3389/fimmu.2025.1527840

In the published article, there was an error in the **Funding** statement. The funder “Duchenne UK” was erroneously excluded. The correct **Funding** statement appears below.

“The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors would like to thank the Parent Project Muscular Dystrophy (PPMD) and Duchenne UK for funding this work.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.